… first weeks of the outbreak of COVID‐19 pandemic in our hospital, we … oral anticoagulants
for cardiovascular diseases. Treatment of COVID‐19 infection is currently based on antiviral …

… The Covid-19 pandemic has resulted in substantial global morbidity and mortality as well as
… , orally bioavailable, direct-acting antiviral therapeutics. Molnupiravir, the orally bioavailable …

… Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel
COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death. Press …

… current knowledge on the antiviral treatment of COVID-19. Investigated antivirals for SARS-…
PF-07304814 (IV) and PF-07321332 (oral) entered phase 1 clinical trials last September in …

… vaccines and highlight the need for other medical treatments such as drug therapy, especially
those that are broad spectrum and can be administered orally, to complement the use of …

… However, data of the above studies indicate the efficacy of favipiravir, we need to wait for
more clinically valid evidence to confirm the positive value of this antiviral agent for COVID-19 …

… This latter phase is more commonly known as “long COVID” [8]. Accordingly, antivirals
are likely to provide benefits against COVID-19 if given early in the course of disease, as …

… In conclusion, we found a signal for benefit from treatment of COVID-19 with an oral antiviral,
especially nirmatrelvir/ritonavir, among patients with cancer. Importantly, our report and …

… of oral antivirals in patients with mild-to-moderate COVID-19 … ) was also found in oral antiviral
recipients compared with their … reached more rapidly in oral antiviral recipients than in the …

… Molnupiravir is one of the oral antiviral drugs under consideration for COVID-19. This oral …
The dose used was 800 mg orally twice daily for 5 days, with or without food, within 5 days …